Montreal (Sept. 26)—Osprey Pharmaceuticals, a privately held biotechnology company, appointed Jack M. Anthony as chief executive officer. Dr. Philip Coggins, who previously
held the position of CEO, will continue as president and assume the new role of chief scientific officer.
South San Francisco, CA (Sept. 26)—Titan Pharmaceuticals, a biopharmaceutical company, appointed Dr. Marc Rubin as president and chief executive officer, effective October 1, 2007.
Rubin will also be a member of the board of directors.
Rockville, MD (Sept. 21)—The US Food and Drug Administration named Janet Woodcock as acting director for the Center for Drug Evaluation and Research (CDER). Woodcock replaces Steven
Galson, who is leaving to become acting surgeon general, effective Oct. 1, 2007. Woodcock will retain her position as FDA
deputy commissioner and permanent chief medical officer. In addition to assuming the day-to-day operational responsibilities
of center director, she will work directly with FDA Commissioner Andrew C. von Eschenbach in launching a national search for
a permanent center director.
In another announcement, FDA named Timothy Coté as the new director of FDA's Office of Orphan Products Development. Coté,
whose experience ranges from medical epidemiology to clinical research, will promote the development of products that demonstrate
promise for the diagnosis or treatment of rare diseases or conditions.
South San Francisco, CA (Sept. 20)—The biopharmaceutical company Novacea announced that John P. Walker was elected as chief executive officer, effective immediately. Walker has been chairman of
Novacea since July 2006, and was named interim CEO in December 2006. He will maintain his role as chairman.
Philadelphia (Sept. 17)—Cardiokine, a privately held specialty pharmaceutical company focused on the development of drugs for the treatment of heart conditions,
announced that David Brand, president and chief executive officer, is leaving the company. The Cardiokine board is expected
to make an announcement shortly regarding Brand's successor.
Paris (Sept. 17)—DBV Technologies, a biopharmaceutical company, expanded its management team with the appointment of Laurent Martin as regulatory-affairs director.
The company also moved to new facilities in central Paris, while maintaining its registered site in Boulogne.
Pittsburgh, PA (Sept. 14)—Mylan Laboratories appointed M. Fabiana Lacerca to senior vice-president and chief compliance officer. Lacerca joins Mylan from Bristol-Myers
Squibb (New York), where she was the director of compliance for Latin America, Canada, and Puerto Rico.
Branford, CT (Sept. 14)—Neurogen, a small-molecule drug-discovery and -development company, appointed Stephen R. Davis president, effective immediately. Davis
previously served as executive vice-president and chief operating officer.
Allegan, MI (Sept. 13)—Mori Arkin, vice-chairman and general manager of Perrigo Global Generics and API, advised the company that he will retire upon the expiration of his current employment agreement on March 17, 2008. Arkin
will remain in his current role until that time, managing the business and working to ensure an orderly transition. Arkin
will remain a member of the company's board of directors and continue to assist the company as needed.